{"transactions":[{"id":2673244,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":138410,"kind":"person","name":"Fricker William","position":1,"cik":"0001752213","reported_name":"Fricker William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Treasurer"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2021-06-10T22:46:28.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":99200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to certain conditions, the options will generally vest in 36 equal installments every month commencing on 11/30/20 and fully vesting on 11/30/23."}],"balance_after":198400,"derivative":{"exercise_price":3.08,"expiration_date":"2030-11-14","underlying":"Common Stock","underlying_shares":99200},"source":{"system":"sec-edgar","filing":"0000950142-21-001939","document":"es210157183_4-fricker.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1719406/000095014221001939/es210157183_4-fricker.xml","form_type":"4"}},{"id":2673243,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":138410,"kind":"person","name":"Fricker William","position":1,"cik":"0001752213","reported_name":"Fricker William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Treasurer"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2021-06-10T22:46:28.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":99200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."}],"balance_after":99200,"derivative":{"exercise_price":3.08,"expiration_date":"2030-11-14","underlying":"Common Stock","underlying_shares":99200},"source":{"system":"sec-edgar","filing":"0000950142-21-001939","document":"es210157183_4-fricker.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1719406/000095014221001939/es210157183_4-fricker.xml","form_type":"4"}},{"id":2999726,"issuer":{"id":145732,"kind":"organization","name":"IMMUNOMEDICS INC","symbol":"IMMU"},"owners":[{"id":138410,"kind":"person","name":"Fricker William","position":1,"cik":"0001752213","reported_name":"Fricker William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-10-27T19:21:39.000Z","date":"2020-10-23","kind":"disposition_to_issuer","acquired":false,"shares":65310,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":65310},"source":{"system":"sec-edgar","filing":"0001104659-20-118646","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/722830/000110465920118646/a4.xml","form_type":"4"}},{"id":3419186,"issuer":{"id":145732,"kind":"organization","name":"IMMUNOMEDICS INC","symbol":"IMMU"},"owners":[{"id":138410,"kind":"person","name":"Fricker William","position":1,"cik":"0001752213","reported_name":"Fricker William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-09-10T18:00:45.000Z","date":"2019-09-06","kind":"grant","acquired":true,"shares":16870,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person was granted stock options pursuant to the Issuer's 2014 Long-Term Incentive Plan. The stock options vest 25% on the first anniversary of the date of grant, and in 6.25% in equal quarterly installments over a three-year period thereafter."}],"balance_after":16870,"derivative":{"exercise_price":13.19,"exercise_date":"2020-09-06","expiration_date":"2026-09-06","underlying":"Common Stock, par value $0.01 per share","underlying_shares":16870},"source":{"system":"sec-edgar","filing":"0001104659-19-049589","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/722830/000110465919049589/a4.xml","form_type":"4"}},{"id":3563464,"issuer":{"id":145732,"kind":"organization","name":"IMMUNOMEDICS INC","symbol":"IMMU"},"owners":[{"id":138410,"kind":"person","name":"Fricker William","position":1,"cik":"0001752213","reported_name":"Fricker William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-04-04T20:33:07.000Z","date":"2019-04-04","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person was granted stock options pursuant to the Issuer's 2014 Long-Term Incentive Plan (the \"Plan\"). The stock options vest 25% on the first anniversary of the date of grant, and 6.25% in equal quarterly installments thereafter."}],"balance_after":15000,"derivative":{"exercise_price":17.87,"expiration_date":"2026-04-04","underlying":"Common Stock, par value $0.01 per share","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-19-020011","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/722830/000110465919020011/a4.xml","form_type":"4"}},{"id":3591911,"issuer":{"id":145732,"kind":"organization","name":"IMMUNOMEDICS INC","symbol":"IMMU"},"owners":[{"id":138410,"kind":"person","name":"Fricker William","position":1,"cik":"0001752213","reported_name":"Fricker William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2019-03-18T16:39:28.000Z","date":"2019-03-14","kind":"grant","acquired":true,"shares":4280,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reporting person was granted stock options pursuant to the Plan. The stock options vest (i) 50% upon the Issuer's receipt of approval from the U.S. Food and Drug Administration for the Issuer's Biologics License Application for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease under the Prescription Drug User Fee Act, and (ii) 50% on the second anniversary of the date of grant."}],"balance_after":4280,"derivative":{"exercise_price":17.94,"expiration_date":"2026-03-14","underlying":"Common Stock, par value $0.01 per share","underlying_shares":4280},"source":{"system":"sec-edgar","filing":"0001104659-19-015616","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/722830/000110465919015616/a4.xml","form_type":"4"}},{"id":3591910,"issuer":{"id":145732,"kind":"organization","name":"IMMUNOMEDICS INC","symbol":"IMMU"},"owners":[{"id":138410,"kind":"person","name":"Fricker William","position":1,"cik":"0001752213","reported_name":"Fricker William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2019-03-18T16:39:28.000Z","date":"2019-03-14","kind":"grant","acquired":true,"shares":8560,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person was granted stock options pursuant to the Issuer's 2014 Long-Term Incentive Plan (the \"Plan\"). The stock options vest 25% on the first anniversary of the date of grant, and in 6.25% in equal quarterly installments thereafter."}],"balance_after":8560,"derivative":{"exercise_price":17.94,"expiration_date":"2026-03-14","underlying":"Common Stock, par value $0.01 per share","underlying_shares":8560},"source":{"system":"sec-edgar","filing":"0001104659-19-015616","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/722830/000110465919015616/a4.xml","form_type":"4"}},{"id":3813728,"issuer":{"id":145732,"kind":"organization","name":"IMMUNOMEDICS INC","symbol":"IMMU"},"owners":[{"id":138410,"kind":"person","name":"Fricker William","position":1,"cik":"0001752213","reported_name":"Fricker William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Stock Options (right to buy)","published_at":"2018-09-18T15:42:21.000Z","date":"2018-09-14","kind":"grant","acquired":true,"shares":5600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person was granted stock options pursuant to the Company's 2014 Long-Term Incentive Plan. The stock options vest 25% on the first anniversary of the date of grant and on a quarterly basis thereafter over a three year period."}],"balance_after":5600,"derivative":{"exercise_price":22.27,"exercise_date":"2019-09-14","expiration_date":"2025-09-14","underlying":"Common Stock, par value $0.01 per share","underlying_shares":5600},"source":{"system":"sec-edgar","filing":"0001171843-18-006609","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/722830/000117184318006609/ownership.xml","form_type":"4"}}]}